A method of increasing total g-sugar in galcanezumab
By adding manganese ions and galactose to the cell culture medium and regulating the glycosylation of cananezumab through fed-batch culture, the problem of not being able to achieve the desired glycosylation pattern in the existing technology has been solved, and the total G sugar content and quality stability have been improved, making it suitable for industrial production.
CN122303151APending Publication Date: 2026-06-30QILU PHARMA CO LTD
Patent Information
- Application Number
- CN202411988579.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-31
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
Existing technologies cannot effectively achieve the desired glycosylation pattern of gacaneduzumab, resulting in its inability to meet clinical needs during production.
Method used
Adding manganese ions and galactose to the cell culture medium and regulating the glycosylation profile of cannabinoids by fed-batch culture, specifically by periodically supplementing manganese ions and galactose during the culture cycle.
Benefits of technology
It significantly increased the total G sugar content in gacaneduzumab, achieving the desired glycosylation profile, without affecting other quality properties, and is simple to operate and easy to implement industrially.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122303151A_ABST
Abstract
This disclosure provides a method for improving the total G sugar yield in garcanetuzumab. Specifically, it provides a method for culturing eukaryotic cells expressing garcanetuzumab in a cell culture medium. By supplementing manganese ions and galactose during cell culture, the total G sugar level in garcanetuzumab is effectively increased to achieve the desired glycosylation profile.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
CGRP antibodies
WO2011156324A1